UBS Group’s Apellis Pharmaceuticals APLS Stock Holding History

UBS Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,500	Closed	-$389K	–	9898
2024 Q3	$389K	Hold	13,500	–	–	﹤0.01%	5406
2024 Q2	$518K	Buy	+13,500	New	+$611K	﹤0.01%	4970
2023 Q3	–	Sell	-49,900	Closed	-$4.55M	–	9426
2023 Q2	$4.55M	Buy	+49,900	New	+$4.31M	﹤0.01%	2686

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

UBS Group's APLS Position: Q2 2026 in Review

UBS Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,206,681 shares — an estimated $250M sold.

UBS Group first reported a position in APLS in Q4 2017 and held it in 34 quarters. The position peaked at $250M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

UBS Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
UBS Group sold 6,206,681 Apellis Pharmaceuticals shares in Q2 2026, an estimated $250M.
UBS Group first reported a position in Apellis Pharmaceuticals in Q4 2017 and held it in 34 quarters.
UBS Group's Apellis Pharmaceuticals position peaked at $250M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.